Literature DB >> 11083274

Activation, differential localization, and regulation of the stress-activated protein kinases, extracellular signal-regulated kinase, c-JUN N-terminal kinase, and p38 mitogen-activated protein kinase, in synovial tissue and cells in rheumatoid arthritis.

G Schett1, M Tohidast-Akrad, J S Smolen, B J Schmid, C W Steiner, P Bitzan, P Zenz, K Redlich, Q Xu, G Steiner.   

Abstract

OBJECTIVE: To investigate whether stress- and mitogen-activated protein kinases (SAPK/MAPK), such as extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase (JNK), and p38 MAPK, are significantly activated in rheumatoid arthritis (RA) synovial tissue compared with their activation in degenerative joint disease; to assess the localization of SAPK/MAPK activation in rheumatoid synovial tissue; and to search for the factors leading to stress kinase activation in human synovial cells.
METHODS: Immunoblotting and immunohistology by antibodies specific for the activated forms of SAPK/MAPK were performed on synovial tissue samples from patients with RA and osteoarthritis (OA). In addition, untreated and cytokine-treated human synovial cells were assessed for SAPK/MAPK activation and downstream signaling by various techniques.
RESULTS: ERK, JNK, and p38 MAPK activation were almost exclusively found in synovial tissue from RA, but not OA, patients. ERK activation was localized around synovial microvessels, JNK activation was localized around and within mononuclear cell infiltrates, and p38 MAPK activation was observed in the synovial lining layer and in synovial endothelial cells. Tumor necrosis factor alpha, interleukin-1 (IL-1), and IL-6 were the major inducers of ERK, JNK, and p38 MAPK activation in cultured human synovial cells.
CONCLUSION: Signaling through SAPK/MAPK pathways is a typical feature of chronic synovitis in RA, but not in degenerative joint disease. SAPK/MAPK signaling is found at distinct sites in the synovial tissue, is induced by proinflammatory cytokines, and could lead to the design of highly targeted therapies.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11083274     DOI: 10.1002/1529-0131(200011)43:11<2501::AID-ANR18>3.0.CO;2-K

Source DB:  PubMed          Journal:  Arthritis Rheum        ISSN: 0004-3591


  122 in total

1.  Expression and activation of mitogen-activated protein kinase kinases-3 and -6 in rheumatoid arthritis.

Authors:  Martine Chabaud-Riou; Gary S Firestein
Journal:  Am J Pathol       Date:  2004-01       Impact factor: 4.307

Review 2.  Signal transduction networks in rheumatoid arthritis.

Authors:  D Hammaker; S Sweeney; G S Firestein
Journal:  Ann Rheum Dis       Date:  2003-11       Impact factor: 19.103

3.  JNK1, but not JNK2, is required in two mechanistically distinct models of inflammatory arthritis.

Authors:  Katja Denninger; Susanne Rasmussen; Jeppe Madura Larsen; Catrine Orskov; Steen Seier Poulsen; Poul Sørensen; Jan Pravsgaard Christensen; Harald Illges; Niels Odum; Tord Labuda
Journal:  Am J Pathol       Date:  2011-08-11       Impact factor: 4.307

4.  Predominant activation of MAP kinases and pro-destructive/pro-inflammatory features by TNF alpha in early-passage synovial fibroblasts via TNF receptor-1: failure of p38 inhibition to suppress matrix metalloproteinase-1 in rheumatoid arthritis.

Authors:  Elke Kunisch; Muktheshwar Gandesiri; Reneé Fuhrmann; Andreas Roth; Rando Winter; Raimund W Kinne
Journal:  Ann Rheum Dis       Date:  2007-01-12       Impact factor: 19.103

5.  Silencing the expression of Ras family GTPase homologues decreases inflammation and joint destruction in experimental arthritis.

Authors:  Daphne de Launay; Jeroen Vreijling; Linda M Hartkamp; Olga N Karpus; Joana R F Abreu; Marjolein A van Maanen; Marjolein E Sanders; Aleksander M Grabiec; Jörg Hamann; Henrik Ørum; Margriet J Vervoordeldonk; Kees Fluiter; Paul P Tak; Kris A Reedquist
Journal:  Am J Pathol       Date:  2010-10-22       Impact factor: 4.307

6.  c-Jun N-terminal kinase is required for metalloproteinase expression and joint destruction in inflammatory arthritis.

Authors:  Z Han; D L Boyle; L Chang; B Bennett; M Karin; L Yang; A M Manning; G S Firestein
Journal:  J Clin Invest       Date:  2001-07       Impact factor: 14.808

Review 7.  The p38 mitogen-activated protein kinase (MAPK) pathway in rheumatoid arthritis.

Authors:  G Schett; J Zwerina; G Firestein
Journal:  Ann Rheum Dis       Date:  2007-09-07       Impact factor: 19.103

8.  Identification of genomic targets downstream of p38 mitogen-activated protein kinase pathway mediating tumor necrosis factor-alpha signaling.

Authors:  Cindy Zer; George Sachs; Jai Moo Shin
Journal:  Physiol Genomics       Date:  2007-07-24       Impact factor: 3.107

9.  Activated protein C inhibits proliferation and tumor necrosis factor α-stimulated activation of p38, c-Jun NH2-terminal kinase (JNK) and Akt in rheumatoid synovial fibroblasts.

Authors:  Sohel M Julovi; Kaitlin Shen; Kelly Mckelvey; Nikita Minhas; Lyn March; Christopher J Jackson
Journal:  Mol Med       Date:  2013-10-24       Impact factor: 6.354

10.  Suppressive effect of leflunomide metabolite (A77 1726) on metalloproteinase production in IL-1beta stimulated rheumatoid synovial fibroblasts.

Authors:  K Migita; T Miyashita; H Ishibashi; Y Maeda; M Nakamura; H Yatsuhashi; H Ida; A Kawakami; T Aoyagi; Y Kawabe; K Eguchi
Journal:  Clin Exp Immunol       Date:  2004-09       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.